Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3963)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 14, 2023 (publication date) through May 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kim ES, Kang B. Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease. World J Gastroenterol 2023; 29(18): 2784-2797 [PMID: 37274072 DOI: 10.3748/wjg.v29.i18.2784] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v29/i18/2784.htm |
| Number | Citing Articles |
| 1 |
Jeffrey Shen, Megumi Sugita, Andrea Linares-Lopez, Suma Shah, Christopher Eckstein, Elijah Lackey. Adalimumab as treatment for neurosarcoidosis: A case series. Journal of the Neurological Sciences 2024; 460: 123018 doi: 10.1016/j.jns.2024.123018
|